drugset / Trial / NCT00040651
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
Phase 1
Terminated
15 enrolled
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Amgen · collabGenzyme, a Sanofi Company · collabUniversity of Pittsburgh · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Scleroderma, or systemic sclerosis (SSc), is a diffuse connective tissue disease characterized by changes in the skin, blood vessels, skeletal muscles, and internal organs. The purpose of this study is to determine the safety and value of self bone marrow transplants after chemotherapy in patients with severe SSc.
Timeline
- Start
- 2002-07
- Primary completion
- 2007-03
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Fludarabine | Small molecule | — | Intravenous |
| Subject | Thymoglobulin | Protein / enzyme biologic | — | Intravenous |